Abstract

The Leishmaniasis is a zoonotic disease that remains a severe public health problem and its burden is increasing. By now there is no anti-leishmaniasis vaccine and as other tripanosomial disease, is treated by limited drugs. First line drug includes pentavalent Antimony such as sodium stibogluconat and meglumine antimoniate that use of these drugs is limited due to side effects, long term treatment, high cost and incidence of drug resistance. It is clear that developing new, effective, cheap and safe drug is necessary for treating Leishmaniasis. In this study new four derivatives of 1-(5-halo-2-thienyl)-2-[5-(5-nitroheteroaryl)]-1,3,4-thiadiazol-2-ylthio)ethanone were synthesized and target compounds were evaluated against the promastigote form of Leishmania major using MTT assay in comparison with control drug (Fluconazole). Concentrations (5-150 Aµg/mL) of synthesized compounds and control drug were prepared and IC50 for each compound was measured. IC50 for 8a-d was 114.98 AµM (44.59A±8.15 Aµg/mL), 118.05 AµM (51.25A±9.08 Aµg/mL), 130.7 AµM (52.78A±12.97 Aµg/mL), and 252.7 AµM (113.3A±5.92 Aµg/mL) respectively that was less than of fluconazole 980 AµM (300 Aµg/mL). The results of this study showed that four synthesized compounds had a significant effect on Leishmania major and have a stronger effect than control drug. It seems that these compounds can be used as an alternative in future.

Authors and Affiliations